Preferred Label : rna, small interfering;

MeSH definition : Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.;

MeSH synonym : small interfering rna; interfering rna, small; sirna; short interfering RNA; interfering RNA, short; RNA, short interfering;

MeSH hyponym : Piwi-Interacting RNA; scan RNA; short hairpin RNA; Trans-Acting siRNA; Piwi Interacting RNA; RNA, Piwi-Interacting; RNA, Piwi Interacting; piRNA; Hairpin RNA, Short; RNA, Short Hairpin; Small Hairpin RNA; Hairpin RNA, Small; RNA, Small Hairpin; shRNA; scnRNA; Small Scan RNA; RNA, Small Scan; Scan RNA, Small; RNA, Scan; Trans Acting siRNA; tasiRNA; siRNA, Trans-Acting; siRNA, Trans Acting;

Related MeSH term : Repeat-Associated siRNA; Repeat Associated siRNA; siRNA, Repeat-Associated; siRNA, Repeat Associated;

MeSH annotation : Do not confuse with defective interfering RNA (diRNA), a viral RNA of DEFECTIVE VIRUSES.;

Wikipedia link : https://en.wikipedia.org/wiki/Sirna;

Is substance : O;

Details


Main resources

You can consult :

Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.

https://www.ema.europa.eu/en/medicines/human/EPAR/amvuttra
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Vutrisiran
Vutrisiran
orphan drug production
vutrisiran
amyloidosis, hereditary, Transthyretin-Related
adult
injections, subcutaneous
product surveillance, postmarketing
RNAi Therapeutics
pregnancy
breast feeding
rna, small interfering
drug evaluation, preclinical

---
https://www.cadth.ca/fr/inclisiran
2021
false
false
false
Canada
French
ALN-PCSsc
Inclisiran
inclisiran
hypercholesterolemia
Primary hypercholesterolemia (disorder)
drug information
insurance, health, reimbursement
ALN-PCS
rna, small interfering

---
https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
ALN-PCSsc
ALN-PCSsc
inclisiran
hypercholesterolemia
Primary hypercholesterolemia (disorder)
mixed dyslipidemia
drug therapy, combination
injections, subcutaneous
Proprotein Convertase 9
product surveillance, postmarketing
hypolipidemic agents
hypolipidemic agents
adult
aged
pregnancy
breast feeding
drug evaluation, preclinical
ALN-PCS
ALN-PCS
rna, small interfering
rna, small interfering

---
https://www.has-sante.fr/jcms/p_3266578/fr/oxlumo-94-5-mg/0-5-ml-lumasiran
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
lumasiran
Lumasiran
injections, subcutaneous
hyperoxaluria, primary
rna, small interfering
renal agents
orphan drug production
adult
adolescent
child
aged
lumasiran
evaluation of the transparency committee

---
https://www.has-sante.fr/jcms/p_3146853/fr/onpattro
2020
false
false
false
France
patisiran
patisiran
amyloidosis, hereditary, Transthyretin-Related
treatment outcome
infusions, intravenous
adult
insurance, health, reimbursement
evaluation of the transparency committee
rna, small interfering
amyloid neuropathies, familial

---
https://www.ema.europa.eu/en/medicines/human/EPAR/oxlumo
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug approval
europe
Lumasiran
Lumasiran
hyperoxaluria, primary
lumasiran
product surveillance, postmarketing
orphan drug production
injections, subcutaneous
Primary hyperoxaluria type 1
pregnancy
breast feeding
adult
adolescent
child
rna, small interfering
rna, small interfering
drug evaluation, preclinical
renal agents
lumasiran

---
https://www.has-sante.fr/jcms/c_2912140/fr/onpattro-patisiran-medicament-du-systeme-nerveux
2019
false
false
false
France
patisiran
patisiran
patisiran
guidelines for drug use
infusions, intravenous
orphan drug production
adult
amyloidosis, hereditary, Transthyretin-Related
treatment outcome
evaluation of the transparency committee
rna, small interfering
rna, small interfering
amyloid neuropathies, familial

---
https://www.has-sante.fr/portail/jcms/c_2912140/fr/onpattro
https://www.has-sante.fr/portail/jcms/c_2912140/en/onpattro-patisiran-medicament-du-systeme-nerveux
2019
false
true
false
false
France
French
treatment outcome
patisiran
orphan drug production
adult
amyloidosis, hereditary, Transthyretin-Related
infusions, intravenous
patisiran
evaluation of the transparency committee
polyneuropathies
Conventional release solution for injection (dose form)
rna, small interfering
guidelines for drug use
rna, small interfering
amyloid neuropathies, familial

---
https://www.cadth.ca/fr/linclisiran-petit-arn-interferent-pour-traiter-lhypercholesterolemie
2019
false
false
false
Canada
French
ALN-PCSsc
drug information
inclisiran
hypercholesterolemia
rna, small interfering
anticholesteremic agents
ALN-PCS

---
https://www.ema.europa.eu/en/medicines/human/EPAR/onpattro
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
patisiran
patisiran
drug approval
europe
orphan drug production
adult
amyloidosis, hereditary, Transthyretin-Related
infusions, intravenous
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
patisiran
drug evaluation, preclinical
rna, small interfering
rna, small interfering
amyloid neuropathies, familial

---
Nous contacter.
18/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.